Biologic characteristics of interval and screen-detected breast cancers

Journal of the National Cancer Institute

Volumn 92, Issue 9, 2000, Pages 743-749

  Gilliland, Frank D ^a,b,c   Joste, Nancy ^c   Stauber, Patricia M ^c   Hunt, William C ^c   Rosenberg, Robert ^c   Redlich, Gillian ^c   Key, Charles R ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034600340     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.9.743     Document Type: Article

References (61)

1. Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish Two-County Trial of Mammographic Screening for Breast Cancer: recent results and calculation of benefit. J Epidemiol Community Health 1989;43:107-14.
2. Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr 1997;22:43-7.
3. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr 1997;22:27-30.
4. Miller AB, Baines C, To T, Wall C. Canadian National Breast Screening Study. 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ 1992;147:1459-76.
5. Alexander FE. The Edinburgh Randomized Trial of Breast Cancer Screening. J Natl Cancer Inst Monogr 1997;22:31-5.
6. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273:149-54.
7. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276: 33-8.
8. Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kelsey CA, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998;209:511-8.
9. Rosenberg RD, Lando JF, Hunt WC, Darling RR, Williamson MR, Linver MN, et al. The New Mexico Mammography Project. Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 1996; 78:1731-9.
10. Schroen AA, Wobbes T, van der Sluis RF. Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 1996;63: 141-4.
11. Senie RT, Lesser M, Kinne DW, Rosen PP. Method of tumor detection influences disease-tree survival of women with breast carcinoma. Cancer 1994;73:1666-72.
12. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992;24: 11-6.
13. Holmberg LH, Tabar L, Adami HO, Bergstrom R. Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 1986;2:27-30.
14. Vitak B. Invasive interval cancers in the Ostergotland Mammographic Screening Programme: radiological analysis. Eur Radiol 1998; 8:639-46.
15. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ. Survival in interval breast cancer in the DOM Screening Programme. Eur J Cancer 1995;31A:1830-5.
16. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med Screen 1995;2: 94-8.
17. Joensuu H, Asola R, Holli K, Kumpulainen E, Nikkanen V, Parvinen LM. Delayed diagnosis and large size of breast cancer after a false negative mammogram. Eur J Cancer 1994; 30A:1299-302.
18. Day N, McCann J, Camilleri-Ferrante C, Britton P, Hurst G, Cush S, et al. Monitoring interval cancers in breast screening programmes: the East Anglian experience. Quality Assurance Management Group of the East Anglian Breast Screening Programme. J Med Screen 1995;2:180-5.
19. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992;84: 781-5.
20. Hollingsworth AB, Taylor LD, Rhodes DC. Establishing a histologic basis for false-negative mammograms. Am J Surg 1993;166: 643-7; discussion 647-8.
21. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancers missed at screening mammography. Radiology 1992;184:613-7.
22. Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ, et al. Screening interval breast cancers: mammographic features and prognosis factors. Radiology 1996; 199:811-7.
23. Brekelmans CT, Collette HJ, Collette C, Fracheboud J, de Waard F. Breast cancer after a negative screen: follow-up of women participating in the DOM Screening Programme. Eur J Cancer 1992;28A:893-5.
24. van Dijck JA, Verbeek AL, Hendriks JH, Holland R. The current detectability of breast cancer in a mammographic screening program. A review of the previous mammograms of interval and screen-detected cancers. Cancer 1993; 72:1933-8.
25. Kopans DB. Detecting breast cancer not visible by mammography [editorial]. J Natl Cancer Inst 1992;84:745-7.
26. Reinigen D, Berman C, Cox C, Baekey P. Nicosia S, Greenberg H, et al. The anatomy of missed breast cancers. Surg Oncol 1993;2:65-75.
27. van Gils CH, Otten JD, Verbeek AL, Hendriks JH, Holland R. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. J Epidemiol Community Health 1998;52:267-71.
28. Sylvester PA, Kutt E, Baird A, Vipond MN, Webb AJ, Farndon JR. Rate and classification of interval cancers in the breast screening programme. Ann R Coll Surg Engl 1997;79: 276-7.
29. Pauli R, Hammond S, Cooke J, Ansell J. Comparison of radiographer/radiologist double film reading with single reading in breast cancer screening. J Med Screen 1996;3:18-22.
30. Burhenne HJ, Burhenne LW, Goldberg F, Hislop TG, Worth AJ, Rebbeck PM, et al. Interval breast cancers in the Screening Mammography Program of British Columbia: analysis and classification. AJR Am J Roentgenol 1994;162:1067-71; discussion 1072-5.
31. Holland R, Mravunac M, Hendriks JH, Bekker BV. So-called interval cancers of the breast. Pathologic and radiologic analysis of sixty-four cases. Cancer 1982;49:2527-33.
32. Martin JE, Moskowitz M, Milbrath JR. Breast cancer missed by mammography. AJR Am J Roentgenol 1979;132:737-9.
33. Ikeda DM, Andersson I, Wattsgard C, Janzon L, Linell F. Interval carcinomas in the Malmo Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR Am J Roentgenol 1992;159:287-94.
34. DeGroote R, Rush BF Jr, Milazzo J, Warden MJ, Rocko JM. Interval breast cancer: a more aggressive subset of breast neoplasias. Surgery 1983;94:543-7.
35. Vitak B, Stal O, Manson JC, Thomas BA, Arnesson LG, Ekelund L, et al. Interval cancers and cancers in non-attenders in the Ostergotland Mammographic Screening Programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 1997;33:1453-60.
36. Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H. Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 1997;75: 762-6.
37. Hatschek T, Fagerberg G, Stal O, Sullivan S. Carstensen J, Grontoft O, et al. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 1989;64:1074-81.
38. Brekelmans CT, van Corp JM, Peeters PH, Collette HJ. Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 1996;78:1220-8.
39. Threlfall AG, Woodman CB, Prior P. Breast screening programme: should the interval between tests depend on age? [letter]. Lancet 1997;349:472.
40. Woodman CB, Threlfall AG, Boggis CR, Prior P. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region. BMJ 1995;310:224-6.
41. Ballard-Barbash R, Taplin SH, Yankaskas BC, Ernster VL, Rosenberg RD, Carney PA, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol 1997;169: 1001-8.
42. Percy C, Van Holten V, Muir C. International Classification of Diseases for Oncology. 2nd ed. Geneva (Switzerland): World Health Organization; 1990.
43. Cunningham J, Hankey B, Lyles B, Percey C, Lynn R, Seiffert J, et al. The SEER Program Code Manual. Rev. ed. June 1992. Bethesda (MD): National Cancer Institute: 1992.
44. Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, et al. p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst 1994;86:1871-3.
45. Elston CW, Ellis IO. Pathological prognostic-factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
46. Biesterfeld S, Noll I, Noll E, Wohltmann D, Bocking A. Mitotic frequency as a prognostic factor in breast cancer. Hum Pathol 1995;26: 47-52.
47. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of breast carcinoma. Am J Clin Pathol 1995;104:614-9.
48. Mehta C, Patel N. StatXact 3 for windows statistical software for exact nonparametric inference. Cambridge (MA): CYTEL Software Corp; 1996.
49. SAS Institute Inc. SAS/STAT software: changes and enhancements through release 6.11. Cary (NC): SAS Institute Inc.; 1996.
50. Arnerlov C, Emdin SO, Lundgren B, Roos G, Soderstrom J, Bjersing L, et al. Breast carcinoma growth rate described by mammographic doubling time and S-phase-fraction. Correlations to clinical and histopathologic factors in a screened population. Cancer 1992;70:1928-34.
51. Winter HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.
52. Merkel DE, McGuire WL. Ploidy, proliferate activity and prognosis. DNA How cytometry of solid tumors. Cancer 1990;65:1194-205.
53. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30:2068-73.
54. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immimohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24:469-76.
55. US Bureau of the Census. Money income of household, families and persons in the United States. Vol. Current Population Reports: P-60 No. 180. Washington (DC): US Govt Print Off: 1991.
56. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995;76:2343-50.
57. Manne U, Myers RB, Srivastava S, Grizzle WE. Re: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer [letter]. J Natl Cancer Inst 1997;89: 585-6.
58. Duncan AA, Wallis MG. Classifying interval cancers. Clin Radiol 1995;50:774-7.
59. Anderson ED, Muir BB, Walsh JS, Kirkpatrick AE. The efficacy of double reading mammograms in breast screening. Clin Radiol 1994; 49:248-51.
60. Feig SA. Strategies for improving sensitivity of screening mammography for women aged 40 to 49 years. JAMA 1996;276:73-4.
61. Warren RM, Duffy SW. Comparison of single reading with double reading of mammograms, and change in effectiveness with experience. Br J Radiol 1995;68:958-62.